Key Developments For Altair Nanotechnologies Inc
Altair Nanotechnologies Inc (ALTI.O) (Consolidated Issue listed on NASDAQ Capital Market)
Altair Nanotechnologies, Inc. To Conduct Nanosensor Research for U.S. Army
Altair Nanotechnologies, Inc. announced that it has signed a research agreement with the U.S. Army RDECOM Acquisition Center for a cost reimbursement contract that could be worth up to $1.75 million. The terms of the contract were signed on September 3, 2009, and run through September 2, 2010. Under the agreement, Altairnano will conduct primary research of sensitive and selective nanosensors in order to determine how single sensing molecules combined with nanoparticles respond to airborne nerve agents and toxic industrial chemicals. Altairnano will also work on incorporating the technology into a portable sensing device that could one day help to protect men and women of the U.S. Army from the threat of chemical weapons.
Altair Nanotechnologies, Inc. Files Shelf Registration
Altair Nanotechnologies, Inc. announced that it has filed a shelf registration statement with the Securities and Exchange Commission (SEC). Upon being declared effective by the SEC, the shelf registration would allow the Company to offer and sell up to $150 million of its common stock, warrants to purchase common stock and units comprised of common stock and warrants from time to time over a three year time period. The terms of any such future offerings would be established at the time of the offering.
Altair Nanotechnologies, Inc. To Provide Proterra With Battery Modules For Electric Buses
Altair Nanotechnologies, Inc. announced that it has been selected by Proterra, a leading manufacturer of zero emission commercial transportation solutions, to deliver advanced battery modules for electric buses. The value of the contract is $898,400. Under terms of the agreement, Altairnano will supply Proterra with advanced battery modules. Each module features Altairnano's 1P10S module configuration. The modules will be used by Proterra for building several EV and hybrid EV buses for municipalities and transportation authorities. The buses are predominately all-electric, 35-foot Proterra FCBE 35 transit buses.
Altair Nanotechnologies, Inc. Assigns Renazorb And Renalan Patents To Spectrum Pharmaceuticals
Altair Nanotechnologies, Inc. announced that it has assigned ownership of all patent rights associated with Renazorb and Renalan to Spectrum Pharmaceuticals, Inc. Spectrum Pharmaceuticals will now have exclusive worldwide rights to Renazorb, Renalan, and any related compounds in any field of use. Under terms of the agreement, Altairnano will receive $750,000 in Spectrum Pharmaceuticals restricted common stock. In addition to the royalty and other payments Altairnano was to receive under the prior license agreement Altairnano will now receive 10% of any fees Spectrum Pharmaceuticals may receive from the sublicensing of Renazorb, Renalan, and any related compounds.
Office of Naval Research Awards Altair Nanotechnologies, Inc. $3.8 Million Contract For Second Phase Of Groundbreaking Shipboard UPS
Altair Nanotechnologies, Inc. announced a $3.8 million contract award from the Office of Naval Research (ONR). This award is for the continued research and design of the Company's large-scale nano lithium titanate energy-storage systems for possible use as an uninterruptible power supply (UPS) on Navy ships. This contract, the continuation of an earlier award announced in 2008, is for the additional engineering, design, and testing of Altairnano's advanced battery systems for use on Navy ships.
